CNS drug development: Part III: Future directions

Journal of Psychiatric Practice

Volumn 17, Issue 1, 2011, Pages 49-52

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

Alzheimer's disease; central nervous system drugs; drug development; drug discovery; drug targets; human genome project

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; DRUG COST; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HUMAN; HUMAN GENOME PROJECT; MENTAL DISEASE; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DISCOVERY; HISTORY, 21ST CENTURY; HUMAN GENOME PROJECT; HUMANS; MENTAL DISORDERS;

EID: 79551542377     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000393844.48593.82     Document Type: Article

References (20)

1. Preskorn SH. CNS drug development: Part I: The early period of CNS drugs. J Psychiatr Pract 2010;16:334-39.
2. Preskorn SH. CNS drug development: Part II: Advances from the 1960s to the 1990s. J Psychiatr Pract 2010;16:413-15.
3. Kaelin WG, Jr. Choosing anticancer drug targets in the postgenomic era. J Clin Invest 1999;104:1503-6.
4. Lai CW. Pharmacogenomics: Methods and protocols. Br J Cancer 2006;94:1553.
5. Gilbert J, Henske P, Singh A. Rebuilding big pharma's Business model. Winhover Information: IN VIVO The Business & Medicine Report; 2003.
6. Egon Zehnder International. Big pharma's new leadership models: Making them work. 2008 (Available at www.egonzehnder.com/global/download/ issue1bigpharma.pdf.
7. Insell T. Who will develop the next generation of medications for mental illness? Rockville, MD: National Institute of Mental Health Director's Blog. March 30, 2010 (available at www.nimh.nih.gov/about/director/2010/who-will- developthe-next-generation-of-medications-for-mentalillness.shtml, accessed September 3, 2010)
8. Nierenberg AA. The perfect storm: CNS drug development in trouble. CNS Spectr 2010;15:282-3 (available at www.cnsspectrums.com/aspx/article-pf.aspx? articleid=2625, accessed September 3, 2010).
9. Markou A, Chiamulera C, Geyer MA, et al. Removing obstacles in neuroscience drug discovery: The future path for animal models. Neuropsychopharmacology 2009;34:74-89.
10. Becker RE, Greig, NH. Alzheimer's disease drug development in 2008 and beyond: Problems and opportunities. Curr Alzheimer Res 2008;5:346-57.
11. Steinmetz KL, Spack EG. The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurol 2009;9(suppl 1):S2.
12. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3, 229-43.
13. Cummings JL. Controversies in Alzheimer's disease drug development. Int Rev Psychiatry 2008;20:389-95.
14. Pritchard JF. Risk in CNS drug discovery: focus on treatment of Alzheimer's disease. BMC Neurosci 2008;9(suppl 3):S1.
15. Chico LK, Van Eldik LJ, Watterson DM. Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov 2009;8:892-909.
16. Alzheimer A. Über eine eigenartige Erkangkung der Hirnrinde [About a peculiar disease of the cerebral cortex]. Originally published in Allgemeine Zeitschr Psychisch-Gerichtliche Medizin 2007;64:146-148).
17. Jarvik L, Greenson H, translators. Alzheimer Dis Assoc Disord 1987;1:3-8.
18. Auguste D. Graeber MB, Kösel S, et al. Histopathology and APOE genotype of the first Alzheimer disease patient. Neurogenetics 1998;1:223-8.
19. Small DH, Cappai R. Alois Alzheimer and Alzheimer's disease: A centennial perspective. J Neurochem 2006;99:708-10.
20. Porsolt RD, Le Pichon M, Jalfre M. Depression: A new animal model sensitive to antidepressant treatments. Nature 1977;266:730-2.